Effects of irbesartan on the expression of matrix metalloproteinase-2 / tissue inhibitor of metalloproteinase-2 in streptozotocin-induced diabetic rat kidney

Chinese Medical Journal

Volumn 118, Issue 12, 2005, Pages 1040-1044

  Liu, Bi Cheng ^a   Xu, Yan ^a   Ma, Kun Ling ^a   Huang, Hai Quan ^a   Yin, Lian Fang ^a   Liu, Dian Ge ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Irbesartan; Matrix metalloproteinase 2; Tissue inhibitor of metalloproteinase 2

Indexed keywords

CREATININE; GELATINASE A; INSULIN; IRBESARTAN; STREPTOZOCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE MODEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; URINALYSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MATRIX METALLOPROTEINASE 2; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TETRAZOLES; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 21344454235     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Portik-Dobos V, Anstadt MP, Hutchinson J, et al. Evidence for a matrix metalloproteinase induction system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002;51:3063-3068.
2. Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin II in diabetic nephropathy. Kidney Int 2000; 58(Suppl 77):93-98.
3. Cao Z, Bonnet F, Davis B, et al. Additive hypotensive and anti-albuminuric effects of angiotensin converting enzyme inhibition and angiotensin receptor antagonist in diabetic spontaneously hypertensive rats. Clin Sci 2001;100:591-599.
4. Thules J, Pouls SS, Jorgensen PE, et al. Adrenergic blockade in diabetic and uninephrectomized rats: effects on renal size and on renal and urinary contents of epidermal growth factor. Nephron 1999;81:172-182.
5. van damme B, Koudstaal J. Measuring glomerular diameters tissue sections. Virchous Arch 1976;369: 283-291.
6. Eikmans M, Baelde JJ, de Heer E, et al. ECM homeostasis in renal diseases: A genomic approach. J Pathol 2003;200:526-536.
7. McLennan SV, Kelly DJ, Cox AJ, et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002;45:268-275.
8. Zaoui P, Cantin JF, Alimardani-Bessette M, et al. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab 2000;26(Suppl 4):S25-S29.
9. Arenas IA, Xu Y, Lopez-Jaramillo P, et al. Angiotensin II induced MMP2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol 2004;286:C779-C784.
10. Liang C, Wu ZG, Ding J, et al. Losartan inhibited expression of matrix metalloproteinurinases in rat atherosclerotic lesions and angiotensin II stimulated macrophages. Acta Pharmacol Sin 2004;25:1426-1432.
11. Wang TL, Yang YH, Chang H, et al. Angiotensin II signals mechanical stretch induced cardiac matrix metalloproteinases expression via JAK-STAT pathway. J Mol Cell Cardiol 2004;37:785-794.